

REVIEW

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *RSC Med. Chem.*, 2024, 15, 2585

Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review

Mary Sravani Galla, Nitika Sharma,[†] Priyanka Mishra[†] and Nagula Shankaraiah *

According to the mounting evidence in the literature, pro-inflammatory mediators/targets activate multiple signalling pathways to trigger illnesses that are ultimately responsible for acute pain, chronic inflammatory diseases, and several auto-immune disorders. Conventional drugs have been ruled out since proteolysis-targeting chimeras (PROTACs) are poised to overcome the limitations of traditional therapies. These heterobifunctional molecules help to degrade the targeted proteins of interest through ubiquitination. This review encompasses current and future aspects of PROTACs in inflammation-mediated and autoimmune targets. Different key points are highlighted and discussed, such as why PROTACs are preferred in this disease area, drawbacks and lessons learnt from the past, the role of linkers in establishing crucial degradation, *in vitro* findings, pharmacokinetics, *in silico* parameters, limitations of PROTACs in clinical settings, and future outcomes.

Received 29th February 2024,
Accepted 8th May 2024

DOI: 10.1039/d4md00142g

rsc.li/medchem

1. Introduction

The dynamic interplay of the synthesis and degradation of the cellular components in living organisms serves as a cornerstone in maintaining homeostasis.¹ The strategy of leveraging the degradation mechanism has surfaced a novel paradigm for treating multiple disease conditions, representing a substantial milestone in modern drug discovery. In inhibitor-based strategies, there is always a setback when it comes to undruggable proteins, their accessible binding sites, or the specific quantifiable functions of these target proteins.² Driving these anomalies, intracellular targeted protein degradation (TPD) encompasses autophagy-lysosome systems [ALS], ubiquitin–proteasome systems [UPS], molecular glues and chaperone-mediated autophagy, with all of them adhering to the disposable mechanism.³ The advent of these bivalent degradations increases the scope for rendering the undruggable events.⁴ TPD could be the next frontier in treating inflammatory and autoimmune diseases.⁵ Unfortunately, drugs such as corticosteroids are still being used in the treatment of many inflammatory conditions for which they are not specifically intended. This is one of the main reasons for the downfall of treatment options in this area. For example, TNF inhibitors

were often used to treat various diseases such as psoriasis, IBD, and arthritis.⁶ However, they failed as a strategy upon identification of the distinct mechanism of these diseases. Consequently, the small molecule inhibitors or biologics, which are targeted in specific areas, are also limited by low organ penetration, attributed to high molecular weights, complicated routes of administration, toxicity, and off-target effects (Fig. 1).^{7,8}

According to the WHO assessment, “chronic inflammatory illness is considered the most significant health hazard to the human population”. To date, many diseases or disorders have no cure and only management is being perpetuated. Emphasizing this, we have identified a list of potential targets, with their diseases highlighted in Table 1. It has been indisputably acknowledged that treating immune-related disorders requires multifaceted approaches since their mechanisms are quite complex and clinically heterogeneous.⁹ In the pathophysiology of various immune checkpoints or endosomal receptors, when activated by pathogens or external/internal stimuli, they undergo an interconnected downstream pathway to awaken the pro-inflammatory genes and cytokines responsible for triggering the disease. Some of the well-known targets and receptors responsible for inflammatory signalling pathways are mentioned in Fig. 2.^{10–12}

PROTACs (proteolysis targeting chimeras) represent a revolutionary breakthrough advancement in TPD. They are also called heterobifunctional molecules meant to hijack the ubiquitin–proteasome system, thus overcoming all the glitches in traditional chemotherapy in terms of selectivity,

Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India.
E-mail: shankar@niperhyd.ac.in, shankarnbs@gmail.com

[†] Contributed equally.




Fig. 1 Illustration of inflammatory/autoimmune disorders that need to be addressed by targeting through PROTACs.

Table 1 A list of important diseases along with their targets in inflammation/autoimmune-mediated diseases

S. no	Disease	Target	Disadvantages of conventional therapy
1.	Asthma and COPD	HDAC-VIII	Toxicities are related to gastrointestinal or constitutional symptoms and haematological abnormalities
2	Neuroinflammation	HDAC-VI	Inhibitors failed to achieve acute and reversible changes in genes
3	Diabetes-induced inflammation	HDAC-III	Limited isoenzyme selectivity, underprivileged pharmacokinetics properties
4	Asthma, rheumatoid arthritis, hidradenitis suppurativa	IRAK3/4	Traditional small-molecule inhibitors are unable to block kinase activity and scaffold signalling of IRAK
5	Rheumatoid arthritis, Alzheimer's neuroinflammation	JAK/STAT	Lipid profile disturbances, thromboembolic complications
6	Asthma, atopic dermatitis	IKT	Poor pharmacokinetics, insufficient target inhibition
7	Crohn's disease, IBD, multiple sclerosis	RIPK2	Toxicity and safety issues during clinical trials; intolerance to therapy over time
8	IBD, autoimmune uveitis	BRD4	Short half-life, off-target effects, development of resistance
9	Systemic lupus erythematosus, Aicardi-Goutières, psoriasis	STING	Poor solubility profile, limited selectivity
10	Inflammatory bowel syndrome, hepatitis	MIF	Low water solubility, pulmonary interstitial fibrosis
11	Asthma, arthritis	MAFF	Limited oral bioavailability
12	Acute lung injury, allergy	H-PGDS	Differences in pharmacokinetics and pharmacodynamics between preclinical animals and humans
13	Alzheimer's and Parkinson's diseases	GSK-3β	Small therapeutic window, low selectivity
14	Neurodegenerative diseases	Keap 1	Off-target effects unpredicted reactions
15	Neuroinflammation, Alzheimer's disease	SHP 2	Higher dose
	Insulin-induced endothelial inflammation		Drug resistance, less efficacy
	COPD, asthma		

catalytic nature,¹³ and potency.^{14,15} Currently, the creation of tailored protein degradation techniques for treating multiple malignancies has been gaining much attention.^{16,17} This golden gateway has diminished nearly

all the major drawbacks of drug discovery using autophagy as a pivotal tool, *i.e.*, a slight modification of the body's destruction machinery, causing the target approach and thus facilitating its degradation through




Fig. 2 The inflammatory signalling pathway and key components: A) NOD1 and NOD2 receptors involving RIPK1&2 to activate NF- κ B for gene translation. B) Toll-like receptors activate the MyD88 complex, followed by IKK and MAPK induction to produce an inflammatory response. C) IL-1R signalling pathway to TRAF-6 and NF- κ B. D) The JAK-STAT pathway activates the tyrosine kinase receptor recruiting JAK-mediated pathway to produce cytokine-responsive genes. E) Cytosolic DNA pathway in activating cGAS STING generating interferon regulating factor.

ubiquitination. Perhaps, implying this technique in inflammatory-mediated diseases would herald a new era in drug innovation.

1.1 Timeline of PROTAC

The Crews and Deshaies group pioneered the groundbreaking idea of PROTAC in 2001.¹⁸ In 2008, Schneekloth *et al.* introduced the first small-molecule PROTAC.¹⁹ The timeline of two decades of PROTACs demonstrates how briskly the technology has progressed from academia to industry to clinical candidates.²⁰

1.2 Mechanism of action

Since the mechanism of PROTACs has been described in numerous reports, its pathway is elucidated in short as follows.²¹ The highly conserved ubiquitin-proteasome system (UPS) is meant for degrading misfolded, non-functional, and other undesirable proteins in the body. It also reported that it is crucially engaged in a diverse array of cellular processes, such as gene transcription,²² protein transport,²³ synaptic plasticity and memory functions.²⁴ The degradation pathway is initiated with ubiquitin-activating enzyme (E1) activating the free ubiquitin, concurrently transferring the ubiquitin to the conjugating enzyme E2.²⁵

The E3 ligase enzyme then catalyses the final step of ubiquitination, which allows the transfer of the ubiquitin molecule from E2 to the target protein *via* forming an isopeptide bond between the lysine residue of the targeted protein and glycine of ubiquitin. Subsequent ubiquitination leads the target protein to be polyubiquitinated.²⁶ Finally, the 26S proteasomal degradation pathway easily recognizes this polyubiquitinated protein for destruction. Ubiquitin molecules are utilised for the subsequent cycle of degradation in this overall process.²⁷

The E3 ligases/degrons are designated as crucial elements in PROTACs, which are responsible for the ubiquitination. Although more than 600 E3 ligases are known to exist in the human body, only a few are being utilized in the development of PROTACs. Von Hippel-Lindau (VHL) and cereblon (CRBN) are the most used E3 ligases. Inhibitors of apoptosis protein (IAP), Kelch-like ECH-associated protein (KEAP1) and mouse double minute 2 (MDM2) are also being explored.^{28,29} In this review, we briefly summarize the status of anti-inflammatory targets being explored as PROTACs and their key findings. In the discussion section, we focus on the crucial topics relevant to the growth needed for anti-inflammatory PROTACs from the perspective of achieving success in bringing the molecule from the bench to the clinic.

Presently one lead molecule, KT-474, has entered the phase II clinical trials targeting IRAK4 through TLR/IL-1R mediated pathways.⁴³

Due to the high degree of similarity between the ATP binding sites of IRAK1 and IRAK4, selective inhibitors of IRAK4 could be valuable for therapeutic strategy in inflammation-mediated diseases like systemic lupus erythematosus. Kargbo *et al.* reasoned that it is particularly challenging to study the catalytic domain of IRAK4's protein since it was highly conserved where the scope of exploration in IRAK4 was delayed. Since the PROTAC could overcome all these limitations, the team developed compounds **5** and **6** (Fig. 4) to provide potent degradation for IRAK4 resulting in IC₅₀ and DC₅₀ values below 30 nM.⁴⁴ Later, many groups focused on achieving a suitable linker for IRAK4 degradation, employing known inhibitors as warheads. Firstly, Nunes *et al.* employed isoquinoline warheads (IRAK4 inhibitor) and various E3 ligands, namely VHL (Von Hippel-Lindau), CRBN (cereblon) or IAP (inhibitor of apoptosis protein). Among them, compound **7**, possessing a fluoro-group, revealed a DC₅₀ of 259 nM through western blotting analysis. Further structural refinement of **7** into **8** exhibited a DC₅₀ value of 151 nM, which includes a spirocyclic pyrimidine linker, more rigid and polar than a flexible linear carbon chain.⁴⁵ Similarly, Chen and co-workers also investigated shorter

linker length PROTACs for IRAK4 observing no significant protein degradation, whereas compound **9** with a polyethylene glycol linker was effective in lowering IRAK4 levels.⁴⁶

Zhang *et al.* explained the inhibitory action of compound **10** by decreased IL-6 production; docking studies revealed that the molecule's cyclopropyl group in the solvent-exposed region is a convenient site for linker conjugation. By structurally altering the cyclopropyl group to a linker, a set of linkers was synthesized and evaluated, of which **10c** and **10d** showed DC₅₀ of 190 nM and 405 nM by immunoblotting.⁴⁷

We know that IRAK is a large group of families, involving IRAK1, IRAK2, and IRAK4 stimulating myeloid differentiation primary response 88 (MyD88)-dependent activation of nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) and thus pro-inflammatory cytokine production. Degorce *et al.* encountered serendipitous results in the discovery of potent IRAK3 inhibitors while studying the IRAK4 protein. The *cis*-isomer of pyrrolotriazine has been employed as an efficient POI ligand with VHL or CRBN as an E3 ligase. CRBN E3 ligases containing PEG linkers showed better degradation than VHL ligands. It was noted that the length of the linker is directly proportional to degradation in the case of CRBN. Compounds **11** and **12** showed selective degradation profiles




Fig. 4 IRAK3 and 4-targeted PROTACs.

with DC_{50} values of 0.052 μ M and 0.002 μ M for IRAK3 by 74% and 98% D_{max} , respectively.⁴⁸

Similar efforts were made by Rowley *et al.*, who studied the IRAK3 protein for controlling the dendritic cell-mediated production of interleukin-12 (IL-12). Crizotinib as the warhead, VHL as the E3 ligase ligand, and compound **13** with *trans*-cyclohexylamide linker resulted in the preferential degradation of IRAK3. Treatment of **13** in THP-1 cell lines resulted in a DC_{50} value of 94 nM and 95% D_{max} . Treatment of dendritic cells with **13** resulted in IRAK3 degradation both in the presence and absence of LPS, along with the significant elevation in IL-12p levels with LPS stimulation.⁴⁹

4. PCAF and GCN5

PCAF (p300/CBP-associated factor) and GCN5 (general control nonderepressible 5) are closely related epigenetic proteins that regulate immune functions in various cellular pathways. According to Zheng *et al.* and Zhuang *et al.*, PCAF and GCN5 are potential targets for treating autoimmune disorders as they cause a reduction in H3K18, H3K9 acetylation, accompanied by NF- κ B, IFN- β (interferon β), TBK1 (TANK binding kinase-1), which are overexpressed in injury, regulating inflammatory action, and modulating immune signaling.^{50–52}

Bassi *et al.* focused on the PCAF/GCN5 PROTACs and employed GSK4027, an active inhibitor of PCAF and GCN5, with CRBN as an E3 ligase for enhancing the activity. Compound **14** (Fig. 5) showed a DC_{50} value of 1.5 nM for PCAF degradation and 3 nM DC_{50} for GCN5 degradation in THP-1 cell lines, and 80% degradation of proteins was observed within 10 min at a concentration of 30 nM. The *cis* (*R,R*) enantiomer of the parent compound GSK4027 is more active than the other enantiomer.⁵³

5. JAK–STAT (Janus kinase-signal transducers and activators of transcription)

Another leading potential target in cytokine signaling is the JAK/STAT pathway involving interleukin-2 and other inflammatory factors, such as γ -interferons. Cytokines binding to JAK receptors initiate STAT transphosphorylation, leading to gene expression for activities like proliferation and differentiation,⁵⁴ which are responsible for numerous disorders, such as rheumatoid arthritis (RA), Alzheimer's disease (AD), inflammatory bowel disease (IBD), and multiple




Fig. 5 PCAF-GCN5 targeted PROTACs.




Fig. 6 Drugs used as JAK–STAT inhibitors.

sclerosis (MS). JAK inhibitors such as tofacitinib **15**, ruxolitinib **16**, baricitinib **17**, (Fig. 6), *etc.*, provided benefits for the improvement of rheumatoid arthritis by altering T-cell activation and natural killer (NK) cell activity.⁵⁵ Although JAK/STAT targets were disclosed decades ago, there are still challenges such as the bulky dose of the drug with a short half-life, side effects like thromboembolism and cross-talk between the JAK/STAT pathway and non-canonical signal transductions.⁵⁶ PROTACs could be a simple answer to the limitations.

Shah *et al.* disclosed PROTACs with pyrimidine and quinoxaline cores as warheads. The primary aim was to develop PROTAC molecules with suitable physicochemical properties to permeate the cells. Among them, the quinoxaline motif showed better permeability than pyrimidine motifs and exhibited more selectivity towards JAK 2. The PBMC (peripheral blood mononuclear cells) assay has been performed to identify the trends regarding cell permeability. The molecules were tested against THP-1 cell lines bearing JAK 1 and 2 proteins, out of which six PROTACs (**21–26**, Fig. 7) were proven to show appropriate degradation.⁵⁷

In 2021, Kargbo filed a patent unravelling PROTAC-mediated degradation targeting Janus kinase (JAK). Pyrrolo-pyrimidines were evaluated for the Caco-2 cell permeability experiment, CRISPER-Cas9 editing, and other biological assays, which revealed that compound **28** has the lowest inhibitory concentration of $EC_{50} = 0.0002 \mu$ M for JAK protein degradation. A simple modification of the linker pattern resulted in a drastic increase in EC_{50} values. The team evaluated PROTACs **29** and **30** containing ruxolitinib and baricitinib (potent JAK inhibitors) as POI ligands with benzamide-containing linkers providing EC_{50} values of 0.00054 μ M and 0.0039 μ M, respectively.⁵⁸

6. ITK (interleukin (IL)-2-inducible T cell kinase)

Jiang *et al.* designed a potent, target-selective ITK (IL-2-inducible T-cell kinase) PROTAC **31** (Fig. 8) to help in degrading inflammatory responses with the inhibition of STAT3 and STAT5 signaling. Compound **31** showed >90% degradation of ITK selectively at a 1 μ M concentration. To




Fig. 7 JAK/STAT targeted PROTACs.

determine its effect on immunology, they treated against the Hut78 cell line and observed a significant decrease in the GATA-3 (transcription factor binding to DNA sequence-3) response.⁵⁹

7. RIPK2 (receptor-interacting serine/threonine protein kinase 2)

RIPK2 functions as a downstream protein for the detection of the NOD1 (nucleotide-binding oligomerization domain 1) and NOD2 (nucleotide-binding oligomerization domain 2) receptors, and further aids in the detection of bacterial protein and regulates the immune system by activating pro-inflammatory signaling in the body.⁶⁰ A pyridinyl imidazole inhibitor and gefitinib showed

significant RIPK2 inhibition and led to improvement in Crohn's disease.⁶¹ RIPK2 is a potential target for treating inflammatory illnesses such as IBD (inflammatory bowel disease), pulmonary sarcoidosis, and multiple sclerosis.⁶² To date, there are no RIPK2 molecules available for clinical use, and reported molecules might not be suitable for further application due to their pan-inhibitions.⁶³

Mares *et al.* developed RIPK2 PROTACs to envision *in vivo* pharmacokinetics and pharmacodynamic profiles by employing aminobenzothiazole-quinoline warheads with IAP E3 ligase. Molecule 32 (Fig. 9) showed a pDC₅₀ of 9.4 ± 0.2 in THP-1 cell lines but had a poor solubility profile. Therefore, it was structurally refined to 33, consisting of pyrazole-quinazoline, to enhance its solubility by adding non-lipophilic groups. Along with reduced lipophilicity and increased solubility, it showed a pDC₅₀ of 7.9. Consequently, to address the large dose dependency, for PROTAC 34, methylene groups increased its binding and potency by ten-fold, with a pIC₅₀ of 8.0.⁶⁴

Bondeson *et al.* developed a RIPK2-based PROTAC for treating autoinflammatory diseases such as Blau syndrome, which is involved in the NF-κB and MAPK activation. Compound 35 resulted in a DC₅₀ of 1.4 nM and a D_{max} of 95% in THP-1 cell lines at a concentration >10 nM.⁶⁵




Fig. 8 ITK targeted PROTACs.




Fig. 9 RIPK2-targeted PROTACs.

8. BRD4 (bromodomain-containing proteins)

Bromodomain-containing proteins expressed by the BET (bromodomain and extra-terminal domain) family have been proven to significantly affect the inflammatory genes through NF-κB or Nrf2 (nuclear factor erythroid 2-related factor 2) pathways.⁶⁶ JQ1 and I-BET are two potent and selective BET inhibitors that have shown their capability in anti-inflammatory activities. As the literature suggests, JQ1 binds with greater affinity to BRD4 than other BET proteins and modulates histone acetylation function, which is responsible

for producing inflammatory genes.⁶⁷ In PROTACs for BRD4, the initial efforts of employing JQ1 as warheads, focusing on the optimal E3 ligases, have been discussed.

Tong *et al.* employed a terpene-based derivative such as bardoxolone, an E3 ligase recruiter, as an electrophilic moiety to establish reversible covalent bonds with the cysteine residue of the KEAP1 (Kelch-like ECH-associated protein) and JQ1 (BRD4 inhibitor), which was employed as a POI to explore the activity of bardoxolone as an E3 ligase. The paper highlights the critical need to explore diverse E3 ligases to withstand the emerging resistance of PROTACs. The descyano derivative **37** (Fig. 10) resulted in the loss of activity to degrade BRD4 in 231 MFP cells, indicating the significance of the α-cyanoenone moiety for the inhibitory action towards BRD4. In general, it has been found that any alteration to the bardoxolone methyl group would significantly impair both its anti-inflammatory efficacy and the activation of the Nrf2 pathway.⁶⁸

iNOS (inducible nitric oxide synthase), COX-2 (cyclooxygenase-2), IL-1β, TNF-α, IL-6, CCL2 and MMP-9 (matrix metalloproteinases) are pro-inflammatory factors that are modulated with BET proteins. A significant reduction in the expression of these proteins was observed with the degradation of BRD2 and BRD4. DeMars *et al.* studied dBET1 in the treatment of neuroinflammatory diseases. JQ1 was a warhead with CRBN E3 ligases. In SIM-A9 microglia cell lines, time-dependent degradation of BRD2 and BRD4 of **38** was observed at the concentration of 1 μM, blocking the production of pro-inflammatory genes.⁶⁹




Fig. 10 BRD4-targeted PROTACs.

9. BTK (Bruton's tyrosine kinase)

Many pro-inflammatory factor modulations were correlated with Bruton's tyrosine kinase (BTK) to maintain immune





Fig. 11 BTK-targeted PROTACs.

haemostasis. X-linked agammaglobulinemia (XLA) is an immunodeficiency disorder caused by the suppression of BTK signalling. Targeting BTK protein would reduce various inflammatory factors such as IL-6, IL-1, TNF- α , type 1-IFN, *etc.* Robert B. Kargbo and co-workers designed and patented BTK degraders; compound **39** (Fig. 11), containing a piperazine linker with CRBN E3 ligase, and compound **40**, containing constrained butane and piperidine rings with

MDM2 E3 ligase, showed minimum DC₅₀ values of 0.0029 μ M and 0.0072 μ M, respectively, resulting in excellent activity.⁷⁰

Given the linker modifications, Tinworth *et al.* compared the degradation profile of covalent binding and reversible binding PROTAC molecules against the BTK target. Halo-PROTACs are a suitable example of covalent binding PROTACs with profound degradation. Compound **42** resulted




Compound	n	DC ₅₀ (μ M)
45	4	10
46	5	9.2
47	6	3.2
48	2	no degradation
49	3	no degradation
50	1	no degradation

Fig. 12 STING-targeted PROTACs.

in concentration-dependent BTK degradation with a DC_{50} of 200 nM for recruiting the VHL E3 ligase. Covalent PROTACs **41**, **43** resulted in no BTK degradation. In contrast, **44** was slightly active towards the degradation. This suggests that non-covalent interactions primarily mediated the degradation as compared to the covalent binding PROTAC. The researchers proposed the reason for this as the blockade of the site by the covalently bound ligand for ubiquitin transfer or the inability of the proteasome to recognize the modified region required for degradation.⁷¹

10. STING (stimulator of interferon genes)

Stimulators of interferon genes (STING) present in the human body aid in the detection of bacterial nucleotides synthesized by the cyclic GMP-AMP synthase enzyme (cGAS) present in bacteria. Under normal circumstances, the human body has a cGAS-STING pathway to regulate innate immune responses. In abnormal conditions, this STING pathway activates pro-inflammatory mediators like cytokines and the release of IFNs to fight against bacterial infections. Liu and co-workers designed PROTACs to target the STING pathway to treat various autoimmune and inflammatory conditions like Aicardi-Goutieres syndrome and systemic lupus erythematosus. Compounds **45–50** (Fig. 12) were synthesized using C-170 as a warhead that interacts with the STING protein through its nitro and furan moieties. In contrast, the benzene ring plays a crucial role by providing a tethering site for the CRBN E3 ligase through a suitable linker. It was observed that the compounds exhibiting α , β -unsaturated carbonyl linkers are biologically active towards degrading the STING protein; compound **47** showed the most satisfactory results with a DC_{50} of 3.2 μ M with time-dependent degradation. *In vivo* studies by ELISA in the kidney tissues of mice showed that **47** could reduce the level of IFN- β , IL-6, and CXCL-10 in a dose-dependent manner.⁷²



Compound	n	R	Ki [nM]	Degradation (%) in 2 μ M
51	3	H	55 $\pm$ 3	not significant
52	4	H	86 $\pm$ 5	21 $\pm$ 7
53	6	H	51 $\pm$ 3	55 $\pm$ 4
54	7	H	71 $\pm$ 5	91 $\pm$ 5
55	9	H	65 $\pm$ 4	64 $\pm$ 2
56	7	CH ₃	55 $\pm$ 12	55 $\pm$ 12

Fig. 13 MIF-targeted PROTACs.

11. MIF (macrophage migration inhibitory factor)

Although MIF is known for its anti-cancer potential, it is also associated with immune responses. In 2021, Xiao *et al.* studied the effects of macrophage migration inhibitory factor (MIF) degradation by employing 7-hydroxycoumarin and 7-hydroxy-3,4-dihydrobenzoxazin-2-one cores as warheads, with cereblon as the E3 ligase ligand. Compound **54** (Fig. 13) was found to be the most potent, with 91% degradation at 2 μ M and 71% degradation against A549 cells. HEK293 cell lines had also been tested with **54**, which resulted in 90% degradation at 200 nM. The cellular uptake of **54** was also confirmed using intrinsic fluorescence microscopy studies.⁷³

12. IKZF (Ikaros zinc-finger transcriptional factors)

Ikaros zinc-finger transcriptional factors (encoded by gene IKZF1) and Aiolos (encoded by gene IKZF3) are critical for immunomodulatory activity and their polymorphism can lead to systemic lupus erythematosus. Two degronimers, **57** and **58** (Fig. 14), have been developed to target the E3 ligase cereblon, which may cause the potential degradation of Aiolos or Ikaros through the ubiquitin–proteasome pathway. The investigation of these compounds for binding to the CRBN-DDB1 (DNA damage binding protein-1) complex using fluorescence polarization assay resulted in values less than 10 μ M K_d .⁷⁴

13. MAFF (v-maf musculoaponeurotic fibrosarcoma oncogene family)

To date, there have been many reports on the anti-inflammatory activity of lathyrane diterpenoids. Wu *et al.* studied PROTACs as a potential strategy for identifying the targets for natural products. ZCY-001 was employed as the




Fig. 14 IKZF-targeted PROTACs.




Fig. 15 MAFF-targeted PROTACs.

warhead for the development of ZCY-PROTAC **59** (Fig. 15) with thalidomide as the E3 ligase linked by a 3-PEG linker, which resulted in the profound inhibition of LPS-stimulated NO (nitric oxide) release. It also showed that MAFF degradation is responsible for inflammatory gene expression. However, individually, lathyrol and thalidomide treatment resulted in no degradation of MAFF, thus confirming that the degradation is induced through the ternary complex formation by PROTAC.⁷⁵

As an extension of this work, the same group designed 15 new PROTACs based on **59** to establish the anti-inflammatory action of lathyrol PROTACs. Different E3 ligase ligands (VHL, cIAP and MDM2) were employed with variations in the linker chains. Compound **60**, having a PEG linker chain and cIAP ubiquitin ligase ligand, showed maximum inhibitory activity with an IC_{50} value of 5.30 ± 1.23 μ M against LPS-induced NO production in RAW264.7 cells.⁷⁶

14. H-PGDS (hematopoietic prostaglandin D synthase)

For the treatment of allergic disorders, targeting H-PGDS (hematopoietic prostaglandin D synthase) would be




Fig. 16 H-PGDS-PROTACs molecules.

beneficial because some allergy disorders are linked to excessive prostaglandin D2 production. However, H-PGDS inhibitors have not shown adequate clinical efficacy. With the advancing research, Yokoo *et al.* approached PROTACs and SNIPERS (specific and nongenetic IAP-dependent protein erasers) as potential treatments (Fig. 16). TFC-007 (a potent inhibitor of H-PGDS with IC_{50} of 83 nM) was employed as a warhead and PROTAC (H-PGDS)-1 **61** was synthesized by employing pomalidomide as a E3 ligase. Significant reduction in H-PGDS was observed with maximum degradation between 100–1000 nM in Human KU812 and MEG-01 cell lines. For better outcomes in degradation and to improve pharmacokinetics, *in silico* simulations were conducted. A library of compounds was designed to dock and understand the binding pattern of the stable ternary complex of PROTAC (H-PGDS). A deeper analysis revealed that the length of the linker is inversely proportional to the stability of the ternary complex. Astonishingly, compound **62** without any linker showed maximum protein degradation with a DC_{50} value of 17.3 μ M against KU812 cell lines. The co-crystal structure of the H-PGDS protein indicates that the *N*-carbonyl piperazine–piperidine moiety of TFC-007 serves as a linker rather than a warhead because it does not bind to the protein. This probably reduced its molecular weight and number of rotatable bonds and rendered compound **62** more druggable with the rule of five chemical spaces.⁷⁷

15. IDO1 (indoleamine 2,3-dioxygenase 1)

IDO1 has been identified as a possible candidate for cancer immunotherapy due to its substantial role in the tumor immune escape mechanism through T-cell regulation. Considering this, Hu *et al.* developed a PROTAC molecule based on Epa (highly selective IDO1 inhibitor) that was employed as a warhead with E3 ligases like lenalidomide and pomalidomide. Compound **63** (Fig. 17), containing seven PEG units, resulted in the degradation of IDO1 with a DC_{50} value and D_{max} of 2.84 μ M L^{-1} and 93%, respectively.⁷⁸




Fig. 17 IDO1-PROTACs molecules.

Later, Bollu *et al.* reported a PROTAC molecule-degrading IDO1 protein. A library of PROTACs was synthesized based on CRBN and VHL-based E3 ligase ligands and with the employment of linrodostat. CRBN-based PROTAC molecules with PEG linkers (<10 carbon atoms) showed a favourable pharmacokinetic profile. Compound **64** with a *para*-attachment to the linker was the most potent, with 94% degradation of IDO1 with a DC_{50} of 0.3290 μ M in U87 cell lines and 0.5438 μ M in GBM43 cell lines.⁷⁹

16. GSK-3 β (glycogen synthase kinase 3 β)

GSK-3 β is regarded as a critical target for treating several neurodegenerative disorders, most notably Alzheimer's disease. GSK-3 β demonstrates its pronounced pro-inflammatory effect, resulting in the loss of neurons. Jiang *et al.* conjugated the GSK-3 β inhibitor with E3 ligases with variable chain length linkers. Through click chemistry, compound **65** (Fig. 18) showed 65.8% degradation of the GSK-3 β at 10 μ M. To examine the inhibitory activity of compound **65** towards the TNF- α , neuroinflammation was induced in the microglia BV2 cells of the mouse. As anticipated, **65** reduced the TNF- α to its basal value, attenuating several inflammatory responses.⁸⁰

17. Keap 1 (Kelch-like ECH associated protein 1)

Lu *et al.* designed a peptide-based PROTAC that acts on Keap1 (Kelch-like ECH associated protein 1) that served as a substrate protein for the Cul3/Rbx1 (cullin-3/RING box protein-1)-dependent E3 ligase complex. The PROTAC facilitates the degradation of tau protein by binding with Keap1, which regulates the Nrf2 signalling pathway related to inflammatory diseases. Ac-LDPETGEYL-OH, a peptide-based PROTAC **66** (Fig. 19), was synthesized and it had a strong affinity for both Keap1 and Tau proteins, with K_d values of 22.8 nM and 763 nM, respectively. PROTAC **66** was crucial for tau degradation, as evidenced by CO-IP, flow cytometry, and western blotting assays in SH-SY5Y, Neuro-2a, and PC-12 cells. Targeting tau breakdown through Keap1 recruitment may be a better way to treat neurodegenerative diseases than suppressing the Nrf2 pathway.⁸¹

Keap1 protein is associated with Nrf2 pathway activation and mediates the oxidative response. Wang *et al.* designed




Fig. 18 GSK-3 β -PROTACs molecules.




Fig. 19 Peptide PROTAC inhibiting Keap1 protein.

PROTAC **67**, which includes a chimeric Keap1-Keap1 peptide to recruit Keap1 target proteins and connect them to the E3 ligase. The peptide sequence was conjugated to the cell-penetrating peptide hPP10 through the C-terminal to obtain **67**, which resulted in 25% of Keap1 protein degradation when treated in HSC-T6 cells (hepatic stellate cells). The degradation of Keap1 protein was found to be associated with the activation of ARE (antioxidant response elements) through the Nrf2 pathway, ultimately leading to the downregulation of TNF- α , IL-1 β , and IL-6. The degradation was confirmed to be induced *via* the ubiquitin-proteasome pathway.⁸²

Ji *et al.* designed PROTACs based on the ARE (antioxidant response elements) sequence as the Nrf2 ligand. The double-stranded oligonucleotide sequence 5'-TCACAGTGACTCAGCA GAATC-3' from the NQO1 (NADPH quinone oxidoreductase 1) promoter was recruited as a warhead. Two series of ARE-PROTAC molecules were synthesized based on CRBN and VHL E3 ligands using a CuAAC (copper-catalyzed azide-alkyne cycloaddition) reaction for conjugation with the Nrf2-DNA ligand. CRBN-based ARE-PROTACs showed favourable depletion levels when tested in A549 cells. Among them, **68** (Fig. 20) is the most potent compound exhibiting a DC_{50} of 1.85 nM against Nrf2 protein and a DC_{50} value of 66 nM against MafG (musculoaponeurotic fibrosarcoma transcription factor G) in A549 cells. Antioxidant activity was also lowered, leading to oxidative damage to cancer cells.⁸³

18. SHP2 (Src homology 2 domain-containing phosphatase 2)

SHP2 is a protein tyrosine phosphatase encoded by the PTPN11 gene and was considered difficult to target because of its highly positively charged nature. In this regard, Wang *et al.*




Fig. 20 Nrf2-targeted PROTACs.




Fig. 21 SHP2-targeted PROTACs.

put efforts into designing a PROTAC molecule with a potent SHP2 inhibitor ($IC_{50} = 98.7$ nM). With the recruitment of the VHL E3 ligand, a series of PROTAC molecules have been designed with varying lengths of alkyl, PEG and piperazinyl linker chains. SHP2-D26 (**69**, Fig. 21) showed maximum SHP2 degradation with DC_{50} values of 6.0 and 2.6 nM in KYSE520 and MV4 cell lines with good aqueous solubility.⁸⁴

19. Perspectives and findings

Undeniably, the complexity of the immune signalling pathways and their underlying mechanisms have made the interventions more challenging. Being the next big therapeutic area after oncology, their advancements are of utmost importance to the research community. In most of the scenarios, the severity of diseases aberrantly depends upon the individual's genetic makeup, making their treatment limited for the targeted therapy. Existing protein therapeutics like monoclonal antibodies (mAbs) bind straightforwardly to the targets, yet their potency is limited towards *in vivo* aspects like bulky molecular weight, poor bioavailability, and high in terms of cost. Comparatively, small molecules have showcased better pharmacokinetic profiles compared to mAbs; nevertheless, their drawbacks in binding to the target, and in protein accumulation resulted in extending the half-life, which is detrimental to the efficacy of drugs. Furthermore, it enabled only 20–25% of druggable targets in the entire human body to be covered. Amalgamating all the instances underscores a pressing need for an innovative approach. The quest was fulfilled with the advent of PROTACs as valuable therapeutic tools surpassing the drawbacks of the aforementioned strategies. Undoubtedly, PROTACs exemplify excellent *in vitro* potency in explored targets like cancer, autoimmune diseases, *etc.*, with established clinical proof of concept. However, there are hurdles to reaching clinical prospects, narrowing the way regarding the solubility and low pharmacokinetic profile of the molecules. However, research efforts have made it possible by the fundamental design, such as optimizing the linker length to stabilize the ternary complex, adding non-lipophilic groups to increase solubility, and nano-formulations for sustained drug delivery. Given the treatment

strategies, the clinical exposure of PROTACs could be confined to a limited duration because long-term use could result in complete loss of the proteins, prompting the risk of developing additional immune diseases. Given that our body system is intricately designed with counter-current mechanisms, only in the case of overexpression or encroachments of a protein due to the loss of self-recognizability or the entry of pathogens is the implication of treatment tactics necessary. Additionally, since they are not fond of inhibition but ultimately degrade the target, the escalation of doses and tolerance buildup might be less/not observed in PROTACs. Given the formulation aspects, the nano-formulations with the extended release of the drug make it possible to prolong the half-life through oral/IV administration.

At present, two degraders, ARV-110 and ARV-471, entered phase II clinical trials for treating prostate and breast cancers. IRAK 4 PROTAC has reached phase II clinical trials (KT-474) to treat hidradenitis suppurativa (HS) and atopic dermatitis (AD). The phase I trial revealed that PROTACs are well tolerated in healthy volunteers at multiple dose frequencies and cope with the safety profile without any adverse effects. A 14 day trial of KT-474 showed reduced IRAK4 levels by over 95% in PBMCs from patients or healthy volunteers. It also dampened the elevated levels of proinflammatory cytokines in the patients' plasma, explaining the drug's high selectivity for IRAK4.⁴³ Another blockbuster clinical candidate in the phase I trial was NX-2127, a degrader of BTK with immunomodulatory activity by IKZF1 degradation. Preclinical evaluation of this molecule ensured the safety parameters conducted by repeated-dose toxicology studies, and cross-species pharmacokinetics.⁸⁵

20. Future perspectives

A more intensive focused study on the anti-inflammatory targets will allow promising clinical candidates to be the next generation of therapeutics. Unlike small molecules, PROTACs offer unlimited benefits like binding, which is specifically a secondary concern for degradation, only relevant groups are mandatory for binding with the protein. This will reduce the molecular weight of the compounds and additional covalent interaction/irreversible bindings, leading to toxicity. These unnecessary groups can be modified as linkers to reduce the additional bulkiness for PROTACs. From the origin of PROTACs, it was majorly confined to anticancer drug development, while other targets received less attention in recognising their potential. In inflammatory/autoimmune diseases, the breach between the existing therapies like NSAIDs and the discovery rate of novel entities is very large. It was observed that the incidence rates of rare/uncurable disorders have been abruptly increasing irrespective of age, gender, species, *etc.* For example, international attention towards irritable bowel syndrome (IBS) is being carried forward as the condition depends on the individual genetic makeup enclosing minimal treatment options. Gratifyingly,

given the progress of BioPROTACs and hybrid PROTACs, the solutions to POI that lack the ligand binding site could be found. The footsteps of immuno-oncology will be an important modality for treating resistance-mediated cancers. All the concerns consolidate to highlight the immediate need for the development of novel PROTACs for future generations.

Author contributions

M. S. Galla: writing – review & editing – original draft. P. Mishra, N. Sharma: literature survey, writing N. Shankaraiah: conceptualization, investigation, writing – review & editing, supervision.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

Authors are thankful to DoP, Ministry of Chemicals & Fertilizers, Govt. of India, New Delhi, for the award of NIPER fellowship.

References

- 1 Z. Yin, H. Popelka, Y. Lei, Y. Yang and D. J. Klionsky, *Cells*, 2020, **9**, 2025.
- 2 Y. Ding, Y. Fei and B. Lu, *Trends Pharmacol. Sci.*, 2020, **41**, 464–474.
- 3 S. J. Hughes, A. Testa, N. Thompson and I. Churcher, *Drug Discovery Today*, 2021, **26**, 2889–2897.
- 4 Q. Q. Zhou, H. T. Xiao, F. Yang, Y. D. Wang, P. Li and Z. G. Zheng, *Pharmacol. Res.*, 2023, **188**, 106627.
- 5 R. Ma, T. P. Ortiz Serrano, J. Davis, A. D. Prigge and K. M. Ridge, *FASEB J.*, 2020, **34**, 13156–13170.
- 6 I. B. McInnes and E. M. Gravallesse, *Nat. Rev. Immunol.*, 2021, **21**, 680–686.
- 7 J. Zheng, D. Chen, J. Xu, X. Ding, Y. Wu, H. C. Shen and X. Tan, *Bioorg. Med. Chem. Lett.*, 2021, **48**, 128229.
- 8 P. Li, Y. Zheng and X. Chen, *Front. Pharmacol.*, 2017, **8**, 460.
- 9 D. S. Pisetsky, *Nat. Rev. Nephrol.*, 2023, **19**, 509–524.
- 10 K. A. Zarembler and P. J. Godowski, *J. Immunol.*, 2002, **168**, 554–561.
- 11 K. Murphy, P. Travers and M. Walport, *Janeway's I.*, Garland Science, 8th edn, 2012.
- 12 G. George, G. L. Shyni and K. G. Raghu, *Inflammopharmacology*, 2020, **28**, 1457–1476.
- 13 D. P. Bondeson, B. E. Smith, G. M. Burslem, A. D. Buhimschi, J. Hines, S. Jaime-Figueroa, J. Wang, B. D. Hamman, A. Ishchenko and C. M. Crews, *Cell Chem. Biol.*, 2018, **25**, 78–87.
- 14 K. M. Riching, S. Mahan, C. R. Corona, M. McDougall, J. D. Vasta, M. B. Robers, M. Urh and D. L. Daniels, *ACS Chem. Biol.*, 2018, **13**, 2758–2770.
- 15 P. Ottis and C. M. Crews, *ACS Chem. Biol.*, 2017, **12**, 892–898.
- 16 M. Toure and C. M. Crews, *Angew. Chem., Int. Ed.*, 2016, **55**, 1966–1973.
- 17 G. E. Winter, D. L. Buckley, J. Paulk, J. M. Roberts, A. Souza, S. Dhe-Paganon and J. E. Bradner, *Science*, 2015, **348**, 1376–1381.
- 18 K. M. Sakamoto, K. B. Kim, A. Kumagai, F. Mercurio, C. M. Crews and R. J. Deshaies, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 8554–8559.
- 19 A. R. Schneekloth, M. Pucheault, H. S. Tae and C. M. Crews, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 5904–5908.
- 20 M. Békés, D. R. Langley and C. M. Crews, *Nat. Rev. Drug Discovery*, 2022, **21**, 181–200.
- 21 (a) P. Ottis and C. M. Crews, *ACS Chem. Biol.*, 2017, **12**, 892–898; (b) M. Toure and C. M. Crews, *Angew. Chem., Int. Ed.*, 2016, **55**, 1966–1973; (c) J. Salami and C. M. Crews, *Science*, 2017, **355**, 1163–1167.
- 22 M. Muratani and W. P. Tansey, *Nat. Rev. Mol. Cell Biol.*, 2003, **4**, 192–201.
- 23 R. C. Aguilar and B. Wendland, *Curr. Opin. Cell Biol.*, 2003, **15**, 184–190.
- 24 T. J. Jarome and F. J. Helmstetter, *Neurobiol. Learn. Mem.*, 2013, **105**, 107–116.
- 25 A. Ocaña and A. Pandiella, *J. Exp. Clin. Cancer Res.*, 2020, **39**, 189.
- 26 D. Nandi, P. Tahiliani, A. Kumar and D. Chandu, *J. Biosci.*, 2006, **31**, 137–155.
- 27 N. Myeku, C. L. Clelland, S. Emrani, N. V. Kukushkin, W. H. Yu, A. L. Goldberg and K. E. Duff, *Nat. Med.*, 2016, **22**, 46–53.
- 28 A. Bricelj, C. Steinebach, R. Kuchta, M. Gütschow and I. Sosič, *Front. Chem.*, 2021, **9**, 707317.
- 29 X. Han and Y. Sun, *MedComm*, 2023, **4**, e290.
- 30 H. K. Namballa, P. Anchi, K. L. Mansa, J. P. Soni, C. Godugu, N. Shankaraiah and A. Kamal, *Bioorg. Chem.*, 2021, **117**, 105461.
- 31 I. M. Adcock, *Br. J. Pharmacol.*, 2007, **150**, 829–831.
- 32 P. J. Barnes, I. M. Adcock and K. Ito, *Eur. Respir. J.*, 2005, **25**, 552–563.
- 33 K. Tomita, P. J. Barnes and I. M. Adcock, *Biochem. Biophys. Res. Commun.*, 2003, **301**, 572–577.
- 34 Y. L. Chung, M. Y. Lee, A. J. Wang and L. F. Yao, *Mol. Ther.*, 2003, **8**, 707–717.
- 35 S. Hendrix, S. Sanchez, E. Ventriglia and S. Lemmens, *Int. J. Mol. Sci.*, 2020, **21**, 4539.
- 36 J. Ran and J. Zhou, *Thorac. Cancer*, 2019, **10**, 405–412.
- 37 B. R. Oh, D. H. Suh, D. Bae, B. Lee and Y. W. Song, *Arthritis Res. Ther.*, 2017, **19**, 154.
- 38 H. M. Blevins, Y. Xu, S. Biby and S. Zhang, *Front. Aging Neurosci.*, 2022, **14**, 879021.
- 39 F. Cao, S. de Weerd, D. Chen, M. R. H. Zwinderman, P. E. van der Wouden and F. J. Dekker, *Eur. J. Med. Chem.*, 2020, **208**, 112800.
- 40 Z. Cao, Z. Gu, S. Lin, D. Chen, J. Wang, Y. Zhao, Y. Li, T. Liu, Y. Li, Y. Wang, H. Lin and B. He, *ACS Chem. Biol.*, 2021, **16**, 2746–2751.

- 41 K. Yang, Y. Zhao, X. Nie, H. Wu, B. Wang, C. M. Almodovar-Rivera, H. Xie and W. Tang, *Cell Chem. Biol.*, 2020, **27**, 866–876.
- 42 J. Chotitumnavee, Y. Yamashita, Y. Takahashi, Y. Takada, T. Iida, M. Oba, Y. Itoh and T. Suzuki, *Chem. Commun.*, 2022, **58**, 4635–4638.
- 43 L. Ackerman, G. Acloque, S. Bacchelli, H. Schwartz, B. J. Feinstein, P. La Stella, A. Alavi, A. Gollerkeri, J. Davis, V. Campbell, A. McDonald, S. Agarwal, R. Karnik, K. Shi, A. Mishkin, J. Culbertson, C. Klaus, B. Enerson, V. Massa, E. Kuhn, K. Sharma, E. Keaney, R. Barnes, D. Chen, X. Zheng, H. Rong, V. Sabesan, C. Ho, N. Mainolfi, A. Slavin and J. A. Gollob, *Nat. Med.*, 2023, **29**, 3127–3136.
- 44 R. B. Kargbo, *ACS Med. Chem. Lett.*, 2019, **10**, 1251–1252.
- 45 J. Nunes, G. A. McGonagle, J. Eden, G. Kiritharan, M. Touzet, X. Lewell, J. Emery, H. Eidam, J. D. Harling and N. A. Anderson, *ACS Med. Chem. Lett.*, 2019, **10**, 1081–1085.
- 46 Y. Chen, Y. Ning, G. Bai, L. Tong, T. Zhang, J. Zhou, H. Zhang, H. Xie, J. Ding and W. Duan, *ACS Med. Chem. Lett.*, 2021, **12**, 82–87.
- 47 J. Zhang, L. Fu, B. Shen, Y. Liu, W. Wang, X. Cai, L. Kong, Y. Yan, R. Meng, Z. Zhang, Y. N. P. Chen, Q. Liu, Z. K. Wan, T. Zhou, X. Wang, P. Gavine, A. del Rosario, K. Ahn, U. Philippar, R. Attar, J. Yang, Y. Xu, J. P. Edwards and X. Dai, *Cell Chem. Biol.*, 2020, **27**, 1500–1509.
- 48 S. L. Degorce, O. Tavana, E. Banks, C. Crafter, L. Gingipalli, D. Kouvinov, Y. Mao, F. Pachi, A. Solanki, V. Valge-Archer, B. Yang and S. D. Edmondson, *J. Med. Chem.*, 2020, **63**, 10460–10473.
- 49 A. Rowley, B. S. Brown, M. Stofega, H. Hoh, R. Mathew, V. Marin, R. X. Ding, R. A. McClure, F. M. Bittencourt, J. Chen, T. Gururaja, T. Kinoshita, X. Wang, A. Rivkin and K. R. Woller, *ACS Chem. Biol.*, 2022, **17**, 1315–1320.
- 50 J. Huang, D. Wan, J. Li, H. Chen, K. Huang and L. Zheng, *Epigenetics*, 2015, **10**, 62–72.
- 51 T. Agaloti, G. Chen and D. Thanos, *Cell*, 2002, **111**, 381–392.
- 52 Q. Jin, L. Zhuang, B. Lai, C. Wang, W. Li, B. Dolan, Y. Lu, Z. Wang, K. Zhao, W. Peng, S. Y. Dent and K. Ge, *EMBO Rep.*, 2014, **15**, 92–1201.
- 53 Z. I. Bassi, M. C. Fillmore, A. H. Miah, T. D. Chapman, C. Maller, E. J. Roberts, L. C. Davis, D. E. Lewis, N. W. Galwey, K. E. Waddington, V. Parravicini, A. L. Macmillan-Jones, C. Gongora, P. G. Humphreys, I. Churcher, R. K. Prinjha and D. F. Tough, *ACS Chem. Biol.*, 2018, **13**, 2862–2867.
- 54 R. Morris, N. J. Kershaw and J. J. Babon, *Protein Sci.*, 2018, **27**, 1984–2009.
- 55 C. J. Malemud, *Ther. Adv. Musculoskeletal Dis.*, 2018, **10**, 117–127.
- 56 X. Hu, J. Li, M. Fu, X. Zhao and W. Wang, *Signal Transduction Targeted Ther.*, 2021, **6**, 402.
- 57 R. R. Shah, J. M. Redmond, A. Mihut, M. Menon, J. P. Evans, J. A. Murphy, M. A. Bartholomew and D. M. Coe, *Bioorg. Med. Chem.*, 2020, **28**, 115326.
- 58 R. B. Kargbo, *ACS Med. Chem. Lett.*, 2021, **12**, 945–946.
- 59 B. Jiang, D. M. Weinstock, K. A. Donovan, H. W. Sun, A. Wolfe, S. Amaka, N. L. Donaldson, G. Wu, Y. Jiang, R. A. Wilcox, E. S. Fischer, N. S. Gray and W. Wu, *Cell Chem. Biol.*, 2023, **30**, 383–393.
- 60 D. J. Philpott, M. T. Sorbara, S. J. Robertson, K. Croitoru and S. E. Girardin, *Nat. Rev. Immunol.*, 2014, **14**, 9–23.
- 61 G. M. Argast, N. Fausto and J. S. Campbell, *Mol. Cell. Biochem.*, 2005, **268**, 129–140.
- 62 P. Canning, Q. Ruan, T. Schwerd, M. Hrdinka, J. L. Maki, D. Saleh, C. Suebsuwong, S. Ray, P. E. Brennan, G. D. Cuny, H. H. Uhlig, M. Gyrd-Hansen, A. Degterev and A. N. Bullock, *Chem. Biol.*, 2015, **22**, 1174–1184.
- 63 Y. Lai, X. Wang, X. Sun, S. Wu, X. Chen, C. Yang, W. Zhang, X. Yu, Y. Tong, F. Ma, H. Zheng, X. Zhang and S. He, *Biochem. Pharmacol.*, 2023, **214**, 115647.
- 64 A. Mares, A. H. Miah, I. E. D. Smith, M. Rackham, A. R. Thawani, J. Cryan, P. A. Haile, B. J. Votta, A. M. Beal, C. Capriotti, M. A. Reilly, D. T. Fisher, N. Zinn, M. Bantscheff, T. T. MacDonald, A. Vossenkamper, P. Dace, I. Churcher, A. B. Benowitz, G. Watt, J. Denyer, P. Scott-Stevens and J. D. Harling, *Commun. Biol.*, 2020, **3**, 140.
- 65 D. P. Bondeson, A. Mares, I. E. D. Smith, E. Ko, S. Campos, A. H. Miah, K. E. Mulholland, N. Routly, D. L. Buckley, J. L. Gustafson, N. Zinn, P. Grandi, S. Shimamura, G. Bergamini, M. Faelt-Savitski, M. Bantscheff, C. Cox, D. A. Gordon, R. R. Willard, J. J. Flanagan, L. N. Casillas, B. J. Votta, B. W. Den, K. Famm, L. Kruidenier, P. S. Carter, J. D. Harling, I. Churcher and C. M. Crews, *Nat. Chem. Biol.*, 2015, **11**, 611–617.
- 66 A. C. Belkina and G. V. Denis, *Nat. Rev. Cancer*, 2012, **12**, 465–477.
- 67 P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, M. Philpott, S. Munro, M. R. McKeown, Y. Wang, A. L. Christie, N. West, M. J. Cameron, B. Schwartz, T. D. Heightman, N. La Thangue, C. A. French, O. Wiest, A. L. Kung, S. Knapp and J. E. Bradner, *Nature*, 2010, **468**, 1067–1073.
- 68 B. Tong, M. Luo, Y. Xie, J. N. Spradlin, J. A. Tallarico, J. M. McKenna, M. Schirle, T. J. Maimone and D. K. Nomura, *Sci. Rep.*, 2020, **10**, 1–8.
- 69 K. M. DeMars, C. Yang, C. I. Castro-Rivera and E. Candelario-Jalil, *Biochem. Biophys. Res. Commun.*, 2018, **497**, 410–415.
- 70 R. B. Kargbo, *ACS Med. Chem. Lett.*, 2021, **12**, 688–689.
- 71 C. P. Tinworth, H. Lithgow, L. Dittus, Z. I. Bassi, S. E. Hughes, M. Muelbaier, H. Dai, I. E. D. Smith, W. J. Kerr, G. A. Burley, M. Bantscheff and J. D. Harling, *ACS Chem. Biol.*, 2019, **14**, 342–347.
- 72 J. Liu, L. Yuan, Y. Ruan, B. Deng, Z. Yang, Y. Ren, L. Li, T. Liu, H. Zhao, R. Mai and J. Chen, *J. Med. Chem.*, 2022, **65**, 6593–6611.
- 73 Z. Xiao, S. Song, D. Chen, R. van Merkerk, P. E. van der Wouden, R. H. Cool, W. J. Quax, G. J. Poelarends, B. N. Melgert and F. J. Dekker, *Angew. Chem., Int. Ed.*, 2021, **60**, 17514–17521.
- 74 R. B. Kargbo, *ACS Med. Chem. Lett.*, 2019, **10**, 276–277.

- 75 Y. Wu, Y. Yang, W. Wang, D. Sun, J. Liang, M. Zhu, H. Li and L. Chen, *Acta Pharm. Sin. B*, 2022, **12**, 4262–4265.
- 76 W. Wang, Y. Liu, L. Xiong, D. Sun, H. Wang, Z. Song, Y. Li, H. Li and L. Chen, *J. Nat. Prod.*, 2023, **86**, 67–781.
- 77 H. Yokoo, N. Shibata, M. Naganuma, Y. Murakami, K. Fujii, T. Ito, K. Aritake, M. Naito and Y. Demizu, *ACS Med. Chem. Lett.*, 2021, **12**, 236–241.
- 78 M. Hu, W. Zhou, Y. Wang, D. Yao, T. Ye, Y. Yao, B. Chen, G. Liu, X. Yang, W. Wang and Y. Xie, *Acta Pharm. Sin. B*, 2020, **10**, 1943–1953.
- 79 L. R. Bollu, P. V. Bommi, P. J. Monsen, L. Zhai, K. L. Lauing, A. Bell, M. Kim, E. Ladomersky, X. Yang, L. C. Platanias, D. E. Matei, M. G. Bonini, H. G. Munshi, R. Hashizume, J. D. Wu, B. Zhang, C. D. James, P. Chen, M. Kocherginsky, C. Horbinski, M. D. Cameron, A. A. Grigorescu, B. Yamini, R. V. Lukas, G. E. Schiltz and D. A. Wainwright, *J. Med. Chem.*, 2022, **65**, 15642–15662.
- 80 X. Jiang, J. Zhou, Y. Wang, X. Liu, K. Xu, J. Xu, F. Feng and H. Sun, *Eur. J. Med. Chem.*, 2021, **210**, 112949.
- 81 M. Lu, T. Liu, Q. Jiao, J. Ji, M. Tao, Y. Liu, Q. You and Z. Jiang, *Eur. J. Med. Chem.*, 2018, **146**, 251–259.
- 82 F. Wang, Y. Zhan, L. Manman, L. Wang, A. Zheng, C. Liu, H. Wang and T. Wang, *ACS Pharmacol. Transl. Sci.*, 2022, **6**, 76–87.
- 83 J. Ji, S. Ma, Y. Zhu, J. Zhao, Y. Tong, Q. You and Z. Jiang, *J. Med. Chem.*, 2023, **66**, 6070–6081.
- 84 M. Wang, J. Lu, M. Wang, C. Y. Yang and S. Wang, *J. Med. Chem.*, 2020, **63**, 7510–7528.
- 85 D. W. Robbins, M. A. Noviski, Y. S. Tan, Z. A. Konst, A. Kelly, P. Auger, N. Brathaban, R. Cass, M. L. Chan, G. Cherala, M. C. Clifton, S. Gajewski, T. G. Ingallinera, D. Karr, D. Kato, J. Ma, J. McKinnell, J. McIntosh, J. Mihalic, B. Murphy, J. R. Panga, G. Peng, J. Powers, L. Perez, R. Rountree, A. Tenn-McClellan, A. T. Sands, D. R. Weiss, J. Wu, J. Ye, C. Guiducci, G. Hansen and F. Cohen, *J. Med. Chem.*, 2024, **67**(4), 2321–2336.